Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
answered, bankruptcy, Biovax, BioVest, Chicago, conservative, daily, death, declared, Deutschland, died, disability, Division, Eastern, economy, efficiently, England, feasible, fixed, fludarabine, GlycArt, GmbH, hematological, histology, Hoechst, ICC, ID, induction, inflation, insolvent, instance, intensify, Journal, logistical, low, Lufkin, macroeconomic, maintenance, Medicine, Merck, merger, methodology, Multidisciplinary, NCCN, neurologic, overstocking, partly, predecessor, pursing, quantitatively, randomized, recession, rolled, Sanofi, simulation, situation, Stabilization, suggested, suit, swap, Symposium, thirty, Thoracic, tool, twelve, unanimously, Unregistered, upfront, VAR, vigorously
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 15.1 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links